A Clinical Study to Evaluate CAD-1883 in Essential Tremor
Status:
Completed
Trial end date:
2019-09-24
Target enrollment:
Participant gender:
Summary
This is an open-label study designed to evaluate the safety, tolerability and efficacy of
CAD-1883, a positive allosteric modulator of the SK channel, administered twice daily orally
to adult patients with ET. Patients with the diagnosis of ET based on the Movement Disorder
Society (MDS) criteria with a documented severity of tremor based on the
clinician-administered TETRAS Performance Subscale are eligible to be enrolled in the study.